Kawai, Masaaki
Takada, Masahiro
Nakayama, Takahiro
Masuda, Norikazu
Shiheido, Hirokazu
Cai, Zhihong
Huang, Yu-Jing
Kawaguchi, Tsutomu
Tanizawa, Yoshinori http://orcid.org/0000-0002-5014-2483
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 24 August 2022
Accepted: 9 November 2022
First Online: 21 November 2022
Declarations
:
: Masaaki Kawai declares honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly and Company, Kyowa-Kirin, MSD, Novartis, and Pfizer. Masahiro Takada declares honoraria for lectures from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, Mitaka Khoki, Nippon Kayaku, and Pfizer; and research grants to institute from ABCSG, AstraZeneca, Daiichi Sankyo, Japan Breast Cancer Research Group, Kyoto Breast Cancer Research Network, Medbis, and Yakult. Takahiro Nakayama reports receiving honoraria for lectures from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, Novartis, Pfizer, and Taiho. Norikazu Masuda declares honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly and Company, and Pfizer; research grants to institute from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, Kyowa-Kirin, MSD, Novartis, Pfizer, and Sanofi; and membership on the board of directors for the Japanese Breast Cancer Society and Japan Breast Cancer Research Group Association. Hirokazu Shiheido, Zhihong Cai, Tsutomu Kawaguchi, and Yoshinori Tanizawa are employees of Eli Lilly Japan K.K. and minor shareholders of Eli Lilly and Company. Yu-Jing Huang is an employee and minor shareholder of Eli Lilly and Company.
: This study was conducted in accordance with the Declaration of Helsinki and Good Pharmacoepidemiology Practices. Per the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects, ethical review and informed consent were not required, as this was a non-interventional, retrospective study that used anonymized patient data.